Clinical trials: Histological Type of Neoplasm
B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia)
BLinatumomab and iNKT in Relapsed B-Cell ALL
This is an open-label, single-arm pilot study evaluating agenT-797, an invariant natural killer T-cell (iNKT) therapy, in combination with routine clinical care blinatumomab in subjects with Philadelphia chromosome-negative…
- Conditions
- B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia), Philadelphia Chromosome-Negative Lymphoblastic Leukemia, CD19-positive B-cell Acute
- Trial name
- BLINK B-ALL (NCT07869368)
- Testing
- Invariant Natural Killer T Cell Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer, Non Hodgkin Lymphoma
PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?
PROACT will establish the effectiveness of the angiotensin-converting enzyme inhibitor (ACEI) enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin lymphoma undergoing adjuvant…
- Trial name
- PROACT (NCT03265574)
- Testing
- Enalapril
- Where
- United Kingdom
- Volunteers
- 111 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
Fallopian Tube Cancer, Ovarian Cancer
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00014690
- Testing
- plevitrexed, topotecan hydrochloride
- Where
- United States
- Sponsor
- AstraZeneca
Malignant Neoplasm of Liver
Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
This is a diagnostic study. Patients were recruited from patients with clinically suspected or confirmed hepatocellular carcinoma and healthy volunteers were recruited for PET/or PET/CT imaging targeting a GPC3-specific probe (in…
- Trial name
- NCT06383520
- Testing
- 68Ga-aGPC3-scFv/Fab
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Germ Cell Tumors, Measurable Disease
Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
This is an open label, single arm, single center, phase 2 study with the use of the antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell tumors who are not cured following first or subsequent…
- Trial name
- Pazotest-01 (NCT01743482)
- Testing
- Pazopanib
- Where
- Italy
- Volunteers
- 43 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Distress, Quality of Life
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study
Background Physical as well as psychosocial complaints are frequently present in patients with a neuroendocrine tumor (NET). Adequate information is seen as an essential aspect of supportive care.
- Conditions
- Distress, Quality of Life, Neuroendocrine Tumor
- Trial name
- WIN (NCT01849523)
- Testing
- Web-based information and support
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Advanced Intra-Ocular Retinoblastoma, Retinoblastoma
Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma
The purpose of this study is to test the safety of the treatment combination of alternating standard chemotherapy and another (melphalan) chemotherapy at different interval schedules.
- Trial name
- NCT02116959
- Testing
- Melphalan, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Alzheimer Disease, Dementia, Mild
Event-Related Potential (ERP) Components in Clinical Diagnosis
In this study, the investigators will use a novel electroencephalogram (EEG) system that participants will wear during a single in-person research session to investigate whether ERPs are now ready for validation as a tool…
- Conditions
- Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
- Trial name
- NCT05673759
- Testing
- Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Boston University
Indolent B-cell Lymphoma, Chronic Lymphocytic Leukaemia
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
The main aims of this clinical study are to find out the maximum dose that can be given safely to patients, the potential side effects of the drug and how they can be managed.
- Conditions
- Indolent B-cell Lymphoma, Chronic Lymphocytic Leukaemia, Waldenström Macroglobulinaemia
- Trial name
- NCT01805375
- Testing
- DI-B4
- Where
- 5 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- Cancer Research UK
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.
- Trial name
- THRIVE (NCT03699475)
- Testing
- rivogenlecleucel, rimiducid, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
This phase II trial studies how well rituximab and pembrolizumab with or without lenalidomide works in treating patients with follicular lymphoma and diffuse large B-cell lymphoma that has returned after a period of improvement.
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
- Trial name
- NCT02446457
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma
- Trial name
- NCT01267812
- Testing
- bortezomib, rituximab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- City of Hope Medical Center
Metastatic Melanoma
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients
This was a retrospective, non-interventional, registry study based on secondary electronic medical record (EMR) data collected in Helsinki and Uusimaa hospital district (HUS data lake), hospital district of Southwest Finland…
- Trial name
- NCT06369428
- Where
- Switzerland
- Volunteers
- 1,795 people
- Sponsor
- Novartis
Leukemia
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002865
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Wake Forest University Health Sciences
B-cell Acute Lymphoblastic Leukemia
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL
In the proposed study, escalating doses of inotuzumab ozogamicin will be added to a standard pediatric inspired re-induction regimen and administered to patients with relapsed or refractory B-cell acute lymphoblastic leukemia…
- Trial name
- ALL-001 (NCT03962465)
- Testing
- Inotuzumab ozogamicin, Prednisone Pill, Daunorubicin
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Virginia
Multiple Myeloma
CART-BCMA Cells for Multiple Myeloma
Open-label, single-center, pilot study to assess the safety and feasibility of infusion of autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCR and 4-1BB costimulatory…
- Trial name
- NCT02546167
- Testing
- CART-BCMA
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pennsylvania
Advanced or Metastatic Hepatocellular Carcinoma
Residual Plasma Concentration of Sorafenib and Adverse Events in CHC
To date, Sorafenib is the only drug therapy to have demonstrated a benefit in overall survival in patients with advanced or metastatic hepatocellular carcinoma.
- Trial name
- PharmacoCHC (NCT03340636)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Caen
Non-Hodgkins Lymphoma, B-cell Lymphoma
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
- Conditions
- Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT01647971
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- TG Therapeutics, Inc.
Ovarian Cancer, Epithelial Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02855944
- Testing
- Chemotherapy, Rucaparib
- Where
- 77 sites in United States, Brazil and 10 more
- Volunteers
- 349 people
- Sponsor
- pharmaand GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.